European Medical Solutions Valuation

Is ALEMS undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of ALEMS when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate ALEMS's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate ALEMS's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ALEMS?

Key metric: As ALEMS is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for ALEMS. This is calculated by dividing ALEMS's market cap by their current revenue.
What is ALEMS's PS Ratio?
PS Ratio	0.6x
Sales	€43.93m
Market Cap	€28.30m

ALEMS key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	1x
Enterprise Value/EBITDA	-33.5x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does ALEMS's PS Ratio compare to its peers?

The above table shows the PS ratio for ALEMS vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	11.6x
MDXH MDxHealth	1.4x	15.5%	€82.4m
BIOS BioSenic	0.6x	n/a	€1.7m
SANION Saniona	13.1x	35.3%	SEK 325.0m
LYTIX Lytix Biopharma	31.4x	137.9%	NOK 337.4m
ALEMS European Medical Solutions	0.6x	n/a	€28.3m

Price-To-Sales vs Peers: ALEMS is good value based on its Price-To-Sales Ratio (0.6x) compared to the peer average (11.6x).

Price to Sales Ratio vs Industry

How does ALEMS's PS Ratio compare vs other companies in the European Biotechs Industry?

38 Companies	Price / Sales	Estimated Growth	Market Cap
Industry Avg.	8.0x	21.8%
ALEMS European Medical Solutions	0.6x	n/a	US$29.42m

38 Companies		Estimated Growth	Market Cap
Industry Avg.	8.0x	43.0%
ALEMS European Medical Solutions	0.6x	n/a	US$29.42m

No more companies

Price-To-Sales vs Industry: ALEMS is good value based on its Price-To-Sales Ratio (0.6x) compared to the European Biotechs industry average (8x).

Price to Sales Ratio vs Fair Ratio

What is ALEMS's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ALEMS PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	0.6x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate ALEMS's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.